No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ARWR240719C25000
- 1.85
- +0.35+23.33%
15min DelayClose Jul 8 15:59 ET
1.85High1.85Low
1.85Open1.50Pre Close1 Volume526 Open Interest25.00Strike Price185.00Turnover51.32%IV5.01%PremiumJul 19, 2024Expiry Date0.57Intrinsic Value100Multiplier10DDays to Expiry1.28Extrinsic Value100Contract SizeAmericanOptions Type0.6245Delta0.1684Gamma20.87Leverage Ratio-0.0427Theta0.0043Rho13.04Eff Leverage0.0167Vega
Intraday
- 5D
- Daily
News
Buy Rating Affirmed for Arrowhead Pharmaceuticals Amid Promising Plozasiran Developments
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Truist Secu
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Cuts Target Price to $60
H.C. Wainwright analyst Patrick Trucchio maintains $Arrowhead Pharmaceuticals(ARWR.US)$ with a buy rating, and adjusts the target price from $90 to $60.According to TipRanks data, the analyst has a su
Arrowhead Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Arrowhead Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Express News | Arrowhead Pharmaceuticals Inc : H.c. Wainwright Cuts Target Price to $60 From $90
Express News | HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Lowers Price Target to $60
Comments
Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia
$Arrowhead Pharmaceuticals(ARWR.US$
$Arrowhead Pharmaceuticals(ARWR.US$
1
$Arrowhead Pharmaceuticals(ARWR.US$
Insiderd selling shares and financials dont look good. Im guessing they dont have anything in the pipeline?
Insiderd selling shares and financials dont look good. Im guessing they dont have anything in the pipeline?
The company's poor performance and the CEO's high pay, despite falling earnings and shareholder value, may upset shareholders. The upcoming AGM on March 14th is a chance for shareholders to hold the board and management accountable.
$Arrowhead Pharmaceuticals(ARWR.US$ why drop today?
$Arrowhead Pharmaceuticals(ARWR.US$ such a odd spot here
Read more